Cutaneous T-Cell Lymphoma Recurrent Terminated Phase 2 Trials for Venetoclax (DB11581)

Also known as: T-Cell Lymphoma Relapsed / Recurrent T-Cell Lymphoma / Recurrent Cutaneous T-cell lymphoma / T-cell lymphoma recurrent / Relapsed T-Cell Lymphoma / T-cell lymphoma NOS recurrent

IndicationStatusPhase
DBCOND0136063 (Cutaneous T-Cell Lymphoma Recurrent)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03552692Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell LymphomaTreatment